drugset / Trial / NCT02544308
Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
Phase 3
Active not recruiting
36 enrolled
University College, London
Cancer Research UK · collabCelgene Corporation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the trial is to establish whether adjuvant therapy with lenalidomide + dexamethasone after radiotherapy can improve progression free survival in patients with high risk solitary bone plasmacytoma compared with RT only.
Timeline
- Start
- 2017-03-10
- Primary completion
- 2026-04
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |